Allecra Therapeutics said June 15 that it raised 22 million euros ($24.7 million) in a Series B round led by Delos Capital. Existing investors Forbion Capital Partners, Edmond de Rothschild Investment Partners, EMBL Ventures and Allecra’s co-Founder Nicholas Benedict also participated. Allecra is a biopharmaceutical company that is developing antibiotics to combat drug-resistant bacterial infections.
Source: PRNewswire
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.